Metastatic pleomorphic sarcoma to left atrium by Hawasli, Ammar H et al.
[Rare Tumors 2009; 1:e1] [page 1]
Metastatic pleomorphic 
sarcoma to left atrium
Ammar H. Hawasli,
1 Rachael Cayce,
2
Trung Luong,
2 Evelyn Taiwo,
1
Michael N. Feliciano
3, 
Sharon C. Reimold,
2,4 John M. DiMaio,
5
Barbara B. Haley
1,2
Departments of 
1Hematology-Oncology,
2Internal Medicine, 
3Pathology,
4Cardiology, and 
5Cardiothoracic Surgery,
University of Texas Southwestern
Medical Center, Dallas, TX, USA
Abstract 
Although  several  thousand  patients  are
diagnosed  with  sarcoma  annually  in  the
United States, metastases to the heart are very
uncommon. In this case report, an overall low
frequency cancer presents masquerading with
common  cardiac  symptomology.  This  case
illustrates the importance for detailed diagnos-
tic cardiac evaluations and heightened suspi-
cion by physicians to consider metastatic dis-
ease to the heart in cancer patients with car-
diovascular complications. Also discussed is a
review  of  surgical  and  chemotherapeutic
options for this problem.
Introduction
A 53-year-old Caucasian gentleman present-
ed with progressive lower back pain, urinary
and bowel incontinence, and lower extremity
swelling  over  a  one  month  period.    He  had
been diagnosed six months prior at an outside
institution with a high-grade pleomorphic sar-
coma  with  focal  myxoid  and  epithelioid  ele-
ments of the duodenum. Small bowel resection
was performed because of bowel obstruction.
Perioperatively, the patient suffered a myocar-
dial infarction (MI) due to focal narrowing of
the left anterior descending artery and a drug-
eluting  stent  was  placed  during  cardiac
catheterization.  Post-operative  transthoracic
echocardiogram (TTE) was interpreted as mild
mitral  valve  thickening,  with  flail  chordae
tendineae and an estimated ejection fraction
of 35-40%. After discharge, the patient was lost
to follow-up. 
Case Report
On  presentation  to  our  facility,  physical
examination revealed normal lower extremity
strength,  focal  tenderness  over  the  sacrum,
pitting edema in the lower extremities and a
murmur  of  mitral  regurgitation  with  basilar
crackles and dullness. Computed tomography
(CT) showed a wedge-shaped splenic infarct
and magnetic resonance imaging (MRI) of the
spine  demonstrated  osseous  metastatic  dis-
ease  involving  the  vertebral  bodies,  with
epidural and neuroforaminal tumor extension
in the sacrum. A TTE was performed in antici-
pation of chemotherapy with adriamycin and
revealed  a  large  vegetation  attached  to  the
anterior leaflet of the mitral valve with pro-
lapse into the left atrium and ventricle (Figure
1A, arrow) and hypoechoic regions within the
cardiac  tissue  (Figure  1A,  arrowhead).  The
patient  was  taken  to  the  operating  room  to
remove the vegetation, biopsy the hypoechoic
mass and replace the mitral valve. A 9 cm veg-
etation was excised from the anterior mitral
valve  leaflet  (Figure  1B,  left  and  middle).
Intraoperatively, the patient was noted to have
diffuse disease throughout the atrial septum
and mitral valve (Figure 1B, right) and the pro-
cedure was terminated. Post-operative cardiac
MRI showed a lobulated cardiac mass infiltrat-
ing the atrial septum, the posterior aortic wall
and the posterior aspect of the anterior mitral
valve  annulus.  In  the  axial  plane,  the  mass
measured at least 5.3 x 2.2 cm and extended to
the superior portion of the left atrium near the
entry  of  the  right  superior  pulmonary  vein
(Figure 1C; mass indicated with arrowheads).
Histology of the atrial mass revealed a high-
grade  pleomorphic  sarcoma,  metastatic  to
heart. Low power frozen sections of the atrial
wall  showed  hypercellularity  (Figure  2A).
Medium and high power frozen (Figure 2B and
C)  and  permanent  (Figure  2D)  sections
showed  tumor  giant  cells  (indicated  with
arrowheads) among spindled and epithelioid
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Figure 1. Echocardiography (A) performed before excision of vegitation (B) and post-
operative cardiac MRI (C).[page 2] [Rare Tumors 2009; 1:e1]
tumor cells. The atrial mass was immunohisto-
chemically  positive  for  vimentin,  confirming
mesenchymal  differentiation  (Figure  2E).
Immunohistochemical stains for other mark-
ers, including CD117, AE1/AE3, desmin, myo-
genin,  caldesmon,  S100,  HMB-34,  calretinin,
CD31 and CD34 were negative (Figure 2F). 
A diagnosis of metastatic cardiac sarcoma
was  established  and  treatment  with  gemc-
itabine  and  docetaxel  was  initiated.  Adria-
mycin-based therapy was not considered sec-
ondary to the patient’s reduced cardiac func-
tion (37% ejection fraction). Five weeks after
initiating  chemotherapy,  the  patient  was
admitted for worsening lower extremity edema
but  denied  shortness  of  breath,  orthopnea,
paroxysmal  nocturnal  dyspnea,  chest  pains,
palpitations, weight gain, or symptoms of tran-
sient  ischemic  attacks.  Electrocardiogram
revealed atrial flutter at 119 beats per minute
with 2:1 block and the old anterolateral infarct.
The patient declined cardioconversion and was
treated with amiodarone. At the time of prepa-
ration of this report, the patient was tolerating
palliative  gemcitabine  and  docetaxel  chemo  -
therapy.
Discussion
Soft-tissue sarcomas are a diverse mix of
cancers with an incidence of 10,390 new cases
diagnosed  annually  in  the  United  States.
1
Despite  aggressive  treatment  with  surgery,
radiation and chemotherapy, outcomes remain
suboptimal as 3,680 (35%) soft-tissue sarcoma
patients  die  annually.
1 Death  secondary  to
metastases is common and sites of metastases
vary depending on the type of soft-tissue sarco-
ma with most types showing a predilection for
the lungs. Metastatic involvement of the heart
by soft-tissue sarcoma has been reported in
the  literature  but  most  cases  of  cardiac
involvement occur in the setting of widespread
metastases.
2 Our  patient  is  among  the  first
reported  cases  of  an  epithelioid  high-grade
pleomorphic sarcoma metastatic to the heart
in absence of known widespread metastases. 
Familiarity with the unique characteristics
of the soft-tissue sarcomas will enable a physi-
cian to identify expected patterns of metastat-
ic spread. One should be suspicious of cardiac
metastases  in  a  soft-tissue  sarcoma  patient
who suddenly develops unexplained congestive
heart failure, new cardiac murmurs, arrhyth-
mias  or  embolic  phenomena.  For  such
patients, metastatic cardiac disease should be
included in the differential diagnosis and fur-
ther  evaluation  with  electrocardiograms,
echocardiograms, and cardiac MRI should be
made. Accurate imaging of cardiac cancer is
very important in the multimodal medical and
surgical  management  of  metastatic  cardiac
sarcoma.
3 In this patient, cardiac metastasis
was  only  incidentally  discovered  during  pre-
chemotherapy  cardiac  evaluation.  However,
several aspects of this patient’s clinical course
suggested the presence of this diagnosis. The
patient’s initial myocardial infarction prompt-
ed  cardiac  catheterization,  which  showed
luminal narrowing assumed to be secondary to
atherosclerotic disease. Yet, on repeat studies,
the patient had no evidence of significant ath-
erosclerotic disease. The patient’s infarct like-
ly resulted from an embolic event originating
from the large mitral valve vegetation or from
extrinsic compression of the artery by tumor.
The splenic lesions noted on CT scans likely
represent  distant  emboli  with  infarction.
Finally,  review  of  the  outside  hospital  TTE
abnormalities noted after the patient’s periop-
erative MI indicated that he had cardiac metas-
tases at initial presentation. A high degree of
suspicion for cardiac involvement by sarcoma
may have hastened a correct diagnosis. 
Conclusions
Management of metastatic sarcoma to the
heart  remains  a  difficult  task.  Some  reports
discuss surgical resection of cardiac metastat-
ic lesions with variable success,
4,5 while others
report the use of cardiac transplantation.
6 In
this case, surgical excision was attempted, but
the extensive infiltrating nature of the tumor
prohibited complete debridement leaving sys-
temic therapy as the only viable option. There
are several generally accepted systemic thera-
pies  for  metastatic  sarcoma  with  most  regi-
mens including doxorubicin as a single agent
7
or in combination with other drugs. The most
widely  employed  combination  chemotherapy
regimens are doxorubicin/dacarbazine,
8,9 dox-
orubicin/ifoxfamide/mesna
10,11 mesna/doxoru-
bicin/ifosfamide/dacarbazine,
12 ifosf  amide/epi -
r  u  bicin/mesna,
13 and gemcitabine/docetaxel.
14-16
However, the use of doxorubicin was felt to be
contraindicated due to the depressed cardiac
function in this patient. If a sarcoma expresses
CD117, imatinib would be a viable treatment
option due to the drug’s oral administration,
favorable toxicity profile, and anti-tumor activ-
ity on some subsets of sarcoma, particularly
gastrointestinal stromal tumors.
17-19 Expression
of this marker is felt to be favorable due to this
relationship. Thus far, reports do not associate
imatinib  with  induction  of  cardiac  failure.
20
Unfortunately our patient’s cardiac tumor did
not  express  CD117  and  the  drug  was  not  a
treatment option. Since metastatic sarcoma to
the heart is a rare occurrence, no prospective
or randomized trials exist to help guide treat-
ment.  In  fact,  there  are  no  data  to  show
whether  systemic  treatment  of  unresectable
cardiac sarcomas significantly improves dura-
tion or quality of life. In the setting of conges-
tive or restrictive heart failure, many of the
first-line chemotherapy options are not feasi-
ble for fear of therapy worsening cardiac func-
tion.  In  our  case,  gemcitabine/docetaxel
chemotherapy was felt to be an active regimen
with controllable toxicity and without potential
devastating cardiac side effects. Tolerance to
the  treatment  regimen  thus  far  has  been
acceptable and the patient is continuing this
chemotherapy. 
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